NCT05393804: Phase 2: Trial of CART Ide-cel (bb2121) Status Post Hematopoietic cell Transplantation
Updated: Feb 5
NCT05393804: Phase 2: A Study of Whether Ide-cel (bb2121) Can Be Made From People With Multiple Myeloma Who Have Had a Hematopoietic Cell Transplant
The purpose of this study is to see if the quality of T cells used to create ide-cel (bb2121) affects how ide-cel prevents cancer from coming back in people with relapsed or refractory multiple myeloma (MM), and who have had a hematopoietic cell transplant.
Sponsor
Memorial Sloan Kettering Cancer Center
ClinicalTrials.gov Identifier: NCT05393804
Official Title: Feasibility Trial of Autologous Anti-B Cell Maturation Antigen Chimeric Antigen Receptor T Cell Therapy Using Ide-Cel for Multiple Myeloma Patients Status Post Hematopoietic Cell Transplantation
First Posted: May 26, 2022
Click here for details on ClinicalTrials.gov
Anti-BCMA CAR T Cells BB2121
anti-BCMA-CAR-transduced T cells BB2121
BCMA-specific CAR-expressing T lymphocytes BB2121
ide-cel
Abecma
BB2121
Biological: Ide-cel (bb2121)
Location
United States, New York